202 related articles for article (PubMed ID: 17032915)
1. Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease.
Sakoda Y; Hashimoto D; Asakura S; Takeuchi K; Harada M; Tanimoto M; Teshima T
Blood; 2007 Feb; 109(4):1756-64. PubMed ID: 17032915
[TBL] [Abstract][Full Text] [Related]
2. Mammalian target of rapamycin inhibitors permit regulatory T cell reconstitution and inhibit experimental chronic graft-versus-host disease.
Sugiyama H; Maeda Y; Nishimori H; Yamasuji Y; Matsuoka K; Fujii N; Kondo E; Shinagawa K; Tanaka T; Takeuchi K; Teshima T; Tanimoto M
Biol Blood Marrow Transplant; 2014 Feb; 20(2):183-91. PubMed ID: 24333142
[TBL] [Abstract][Full Text] [Related]
3. Impaired thymic negative selection causes autoimmune graft-versus-host disease.
Teshima T; Reddy P; Liu C; Williams D; Cooke KR; Ferrara JL
Blood; 2003 Jul; 102(2):429-35. PubMed ID: 12663438
[TBL] [Abstract][Full Text] [Related]
4. CD4+ T cells generated de novo from donor hemopoietic stem cells mediate the evolution from acute to chronic graft-versus-host disease.
Zhang Y; Hexner E; Frank D; Emerson SG
J Immunol; 2007 Sep; 179(5):3305-14. PubMed ID: 17709547
[TBL] [Abstract][Full Text] [Related]
5. Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4+ and CD8+ T cells.
Wu T; Young JS; Johnston H; Ni X; Deng R; Racine J; Wang M; Wang A; Todorov I; Wang J; Zeng D
J Immunol; 2013 Jul; 191(1):488-99. PubMed ID: 23709681
[TBL] [Abstract][Full Text] [Related]
6. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
7. Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs host disease.
Holländer GA; Widmer B; Burakoff SJ
J Immunol; 1994 Feb; 152(4):1609-17. PubMed ID: 7907102
[TBL] [Abstract][Full Text] [Related]
8. Lethal murine graft-versus-host disease induced by donor gamma/delta expressing T cells with specificity for host nonclassical major histocompatibility complex class Ib antigens.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Barrett TA; Bluestone JA; Vallera DA
Blood; 1996 Jan; 87(2):827-37. PubMed ID: 8555509
[TBL] [Abstract][Full Text] [Related]
9. Fas-deficient lpr mice are more susceptible to graft-versus-host disease.
van Den Brink MR; Moore E; Horndasch KJ; Crawford JM; Hoffman J; Murphy GF; Burakoff SJ
J Immunol; 2000 Jan; 164(1):469-80. PubMed ID: 10605044
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
11. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
12. Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease.
Schultz KR; Bader S; Paquet J; Li W
Blood; 1995 Dec; 86(11):4344-52. PubMed ID: 7492796
[TBL] [Abstract][Full Text] [Related]
13. Graft-versus-host-disease-associated thymic damage results in the appearance of T cell clones with anti-host reactivity.
van den Brink MR; Moore E; Ferrara JL; Burakoff SJ
Transplantation; 2000 Feb; 69(3):446-9. PubMed ID: 10706060
[TBL] [Abstract][Full Text] [Related]
14. Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients.
Marks L; Altman NH; Podack ER; Levy RB
Transplantation; 2004 Mar; 77(6):804-12. PubMed ID: 15077018
[TBL] [Abstract][Full Text] [Related]
15. Fas ligand-deficient gld mice are more susceptible to graft-versus-host-disease.
van den Brink MR; Moore E; Horndasch KJ; Crawford JM; Murphy GF; Burakoff SJ
Transplantation; 2000 Jul; 70(1):184-91. PubMed ID: 10919598
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-12 prevents severe acute graft-versus-host disease (GVHD) and GVHD-associated immune dysfunction in a fully major histocompatibility complex haplotype-mismatched murine bone marrow transplantation model.
Yang YG; Dey B; Sergio JJ; Sykes M
Transplantation; 1997 Nov; 64(9):1343-52. PubMed ID: 9371678
[TBL] [Abstract][Full Text] [Related]
17. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
Johnson BD; Becker EE; LaBelle JL; Truitt RL
J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
[TBL] [Abstract][Full Text] [Related]
18. Intermediate TCR cells can induce graft-versus-host disease after allogeneic bone marrow transplantation.
Weerasinghe A; Kawamura T; Moroda T; Seki S; Watanabe H; Abo T
Cell Immunol; 1998 Apr; 185(1):14-29. PubMed ID: 9636679
[TBL] [Abstract][Full Text] [Related]
19. TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J-->C57BL/6J x bm12)F1 mice.
Brown GR; Lee E; Thiele DL
J Immunol; 2002 Mar; 168(6):3065-71. PubMed ID: 11884480
[TBL] [Abstract][Full Text] [Related]
20. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans.
Martin PJ
J Exp Med; 1993 Aug; 178(2):703-12. PubMed ID: 8101864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
